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Abstract. Over the latest decade, the role of microRNAs 
(miRNAs/miRs) has received more attention. miRNAs are 
small non-coding RNAs that may serve a role as oncogenes 
or tumor suppressor genes. Certain miRNAs regulate the 
apoptosis pathway by influencing pro‑ or anti‑apoptotic genes. 
We hypothesized that increases in the expression of B cell 
lymphoma 2 (BCL2) and BCL2-like 1 (BCL2L1) genes, which 
have been reported in various types of cancer tissues, may be 
due to the downregulation of certain miRNAs. The present 
study aimed to identify miRNAs that target BCL2 and BCL2L1 
anti-apoptotic genes in prostate cancer (PCa) clinical tissue 
samples. Certain candidate miRNAs were selected bioinfor-
matically and their expression in PCa samples was analyzed 
and compared with that in benign prostatic hyperplasia 
(BPH) tissue samples. The candidate miRNAs that targeted 
BCL2 and BCL2L1 genes were searched in online databases 
(miRWalk, microRNA.org, miRDB and TargetScan). A total 
of 12 miRNAs that target the 3'-untranslated region of the 
aforementioned genes and/or for which downregulation of 
their expression has previously been reported in cancer tissues. 
A total of 30 tumor tissue samples from patients with PCa and 
30 samples tissues from patients with BPH were obtained 
and were subjected to reverse transcription-quantitative poly-
merase chain reaction for expression analysis of 12 candidate 
miRNAs, and the BCL2 and BCL2L1 genes. Additionally, 
expression of 3 finally selected miRNAs and genes was evalu-
ated in prostate cancer PC3 and DU145 cell lines and human 
umbilical vein endothelial cells. Among 12 miRNA candi-
dates, the expression of miR-1266, miR-185 and miR-30c-2 
was markedly downregulated in PCa tumor tissues and cell 
lines. Furthermore, downregulation of these miRNAs was 
associated with upregulation of the BCL2 and BCL2L1 genes. 
An inverse association between three miRNAs (miR-1266, 
miR-185 and miR-30c-2) and two anti-apoptotic genes (BCL2 
and BCL2L1) may be considered for interventional miRNA 
therapy of PCa.
Introduction
Prostate Cancer (PCa) is the most common type of cancer 
in men >40 years of age (1). Over the past decade, the age 
at mortality and the rate of mortality caused by PCa have 
declined. After lung cancer, PCa is the second leading cause of 
cancer-associated mortality in men (2). In 2015, the American 
Cancer Society announced that >220,000 men were diagnosed 
with PCa; it was anticipated that 25,000 of these men would 
succumb as a result of their cancer (3).
An increase in the serum level of prostate‑specific antigen 
(PSA) or an abnormal digital rectal examination result may be 
warning signs for PCa. There is no general consensus on the 
normal PSA level in men of different ages and therefore, its use 
remains undetermined for an accurate and early diagnosis (4). 
One of the main difficulties in treating PCa is the resistance of 
cancer cells to current therapy methods (5).
MicroRNAs (miRNAs/miRs) are non-coding ribonucleic 
acids, 18-25 nucleotides in length, that are highly conserved 
across species. These molecular structures are involved in 
controlling physiological and pathological cellular processes. 
miRNAs primarily bind to the 3'-untranslated region 
(3'-UTR) of target mRNA(s) through complementary base 
pairing, which will cause degradation of mRNA or halt its 
translation (6-8).
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As of yet, as demonstrated in the miRBase (www.mirbase.
org), >21,264 miRNAs have been identified. With regards to 
cancer, miRNAs may be oncogenic or tumor suppressors. 
Therefore, it is reasonable to assume that cancer may be 
controlled by altering the expression of miRNAs (9).
In recent decades, the role of miRNAs has been studied in 
numerous types of human and animal cancer. The expression 
of miRNAs has been studied in cancerous and healthy cells, 
and different resulting profiles have revealed that miRNAs may 
control certain cell cycle pathways, including apoptosis (10-12). 
Defective apoptosis pathways may be considered one of the 
most important features of cancer cells (13). At present, two 
main pathways for apoptosis have been discovered in cells. 
The extrinsic pathway involves receptors [first apoptosis 
signal receptor (FAS), complement receptor 4/5 (CR4/5), and 
tumor necrosis factor receptor (TNFR)] on the cell surface, 
which, after binding with their specific ligands (FAS ligand, 
TNF-related apoptosis-inducing ligand and threose nucleic 
acid), oligomerize the FAS-associated death domain (FADD) 
and activate apoptosis (14).
The second pathway is a mitochondrial pathway 
that is regulated by B cell lymphoma 2 (BCL2) family 
proteins. BCL2 family proteins include pro-apoptotic 
[BCL2-associated X protein (BAX) and BCL2 homolo-
gous killer protein (BAK)] and anti-apoptotic [BCL2 and 
BCL2-like 1 (BCL2L1)] members. The balance between 
pro- and anti-apoptotic proteins regulates the permeability 
of the mitochondrial membrane (15-17). Although the exact 
mechanisms of mitochondrial proteins remain clear, confor-
mational changes in BAK and BAX lead to pore formation 
in the outer mitochondrial membrane and cytochrome C 
release (18), which eventually leads to apoptosis. BCL2L1, 
which is a member of the BCL2 protein group, serves a role 
in regulating mitochondrial apoptosis through regulating the 
release of pro-apoptotic factors from the mitochondria (15). 
Mitochondrial apoptosis pathway stimulation is induced 
by DNA damage or cytotoxic drugs that eventually cause 
cytochrome C to be released from the mitochondria through 
the permeated membrane and apoptosis to take place (16,17). 
The BCL2L1 gene is transcribed to a few isoforms. The 
longest of these is translated to a 233-amino acid protein with 
anti-apoptotic function (15,19,20).
Considering the role of miRNAs in the suppression of 
anti-apoptotic genes, it can be assumed that downregulation 
of these miRNAs may be associated with the initiation or 
maintenance of cancer (21).
The present study analyzed the association between the 
expression of BCL2 and BCL2L1 anti-apoptosis genes and 
the expression of the miRNAs that target them. Using bioin-
formatics and literature review, a few miRNAs that had been 
validated for having or were predicted to have inhibitory effects 
on the BCL2 and BCL2L1 genes by targeting their 3'-UTR were 
nominated. Among them, 12 miRNAs were selected based 
on their features, including being bound to more than one 
anti-apoptotic gene, having more complementary base pairing 
nucleotides in the seed region, being predicted by miRNA 
algorithm tools and novelty. Finally, expression profiles of the 
12 selected miRNAs taken from the PCa tissue samples were 
examined and compared with those taken from the benign 
prostatic hyperplasia (BPH) tissue samples. Simultaneously, 
expression profiles of the target genes (BCL2 and BCL2L1) 
were analyzed.
Materials and methods
miRNA selection. Four databases were used to identify 
12 miRNAs. One score was given for each target predic-
tion by any of the databases and the miRNAs with the 
12 highest overall scores were selected. miRWalk (http://
zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) provides a 
validated and predicted miRNA-target interaction database 
of human, mouse and rat genes. It aggregates and compares 
results from other miRNA-to-mRNA databases. miRanda 
(http://34.236.212.39/microrna/getDownloads.do) is an 
online database for experimentally observed microRNA 
expression patterns and predicted microRNA targets. 
miRDB (www.mirdb.org/) is also an online database for 
predicted miRNA targets in animals. TargetScan (www.
targetscan.org/) miRNA target predictor software has 
context score contribution to include seed pairing stability 
and target site.
Clinical samples. The present study was approved by the 
Pasteur Institute of Iran Ethical Review Board. Written 
informed consent was obtained from all participants prior 
to the clinical samples being obtained. PCa tissues (n=30) 
were collected following radical prostatectomy from 
untreated patients with PCa who were 48-80 years old 
(mean, 65.66 years). Within 1 h of prostatectomy, the speci-
mens were dissected by a uropathologist (Hashemi Nejad 
Clinical Research Developing Center, Tehran, Iran) and 
were stored at ‑80˚C until RNA extraction. Only samples 
containing >70% tumor cells were included in the study. The 
Gleason score, pathological stage and histological diagnosis 
were assessed according to the guidelines of the Union for 
International Cancer Control 2002 (22). As a control group, 
RNA was prepared from prostate tissue samples obtained 
from patients undergoing radical surgery for BPH (n=30). 
The absence of cancer cells in the prostate tissue was veri-
fied. In all cases, tissue samples were randomly selected. 
Clinical samples were obtained from the Department of 
Pathology, Hashemi Nejad Hospital (Tehran, Iran) between 
2014 and 2015 (Table I).
Cell lines. The human PCa PC3 and DU145 cell line, and 
human umbilical vein endothelial cells (HUVECs) were 
purchased from the Cell Bank of the Pasteur Institute of Iran 
(Tehran, Iran). Cells were cultured in RPMI-1640 medium, 
supplemented with 10% fetal bovine serum, 100 U/ml peni-
cillin and 100 mg/ml streptomycin (all Gibco; Thermo Fisher 
Scientific, Inc., Waltham MA, USA) at 37˚C with 5% CO2.
RNA extraction
Tissues. To begin with, 10-50 mg samples of frozen muscle 
in pieces were homogenized in 1 ml 100% Triazole (Merck 
KGaA, Darmstadt, Germany) in 15 ml centrifuge tubes. During 
the homogenization process, the tubes were kept cold using 
liquid nitrogen. The tubes were then left at room temperature 
for 5 min to permit complete dissociation of nucleoprotein 
complexes. Subsequently, 100 µl 1-Bromo-3-chloropropane 
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was added to each tube, vortexed for 10 sec and incubated 
at room temperature for 10 min. Following centrifugation 
at 20,817 x g ‑for 15 min at 4˚C, the mixture separated into 
3 layers; the lower phenol-red chloroform phase, the relatively 
turbid middle interphase and the colorless upper aqueous phase. 
The latter was carefully transferred into unused 1.5 ml tubes. 
Following the addition of an equal volume of isopropanol 
and brief vortexing, the samples were stored at 4˚C for 24 h, 
which was followed by centrifugation at 6,797 x g, for 1 h at 
4˚C. The precipitate RNA was visualized as a small palette. 
Subsequently, the supernatant was carefully removed and the 
palette was washed with 1 ml 75% ethanol and centrifuged at 
6,797 x g for 5 min at 4˚C. The supernatant was removed and the 
pellet was air dried for 2-3 min and re-dissolved in 100 µl diethyl 
pyrocarbonate-treated water. The quantity and quality of the 
purified RNA samples were determined spectrophotometrically 
(A260/280 >2.0; A260/230 >1.8), using a NanoDrop ND-2000 
Spectrophotometer (Thermo Fisher Scientific, Inc.).
Cell lines. Total RNA was extracted from cells using a miRN 
easy Mini kit (Qiagen GmbH, Hilden, Germany). In brief, 
cells were seeded (to ~90% confluency, ~100,000 cells/well) 
onto 24-well plates for 24 h, and were then disrupted by the 
addition of Qiazole (Qiagen GmbH, ), prior to the samples 
being separated to three phases by the addition of chloroform 
(Merck KGaA). Ethanol (70%; Merck KGaA) was added to 
the aqueous phase to precipitate RNA; finally, according to the 
manufacturer's protocol, following washing and centrifuging, 
total RNA was extracted.
cDNA synthesis
microRNA. Due to its specific structure, first strand synthesis 
of cDNA was performed using an miScript II RT kit (Qiagen 
GmbH, Hilden, Germany), which first adds a poly‑A tail to the 3' 
overhang of molecules and then incorporates a tagged sequence 
upstream to the poly-T sequence for the universal reverse 
primer used in subsequent reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR).
mRNA. A PrimeScript RT reagent kit (Takara Bio, Inc., 
Otsu, Japan) was used for reverse transcription of molecules, 
according to the manufacturer's protocols.
Table I. Patient demographics and clinicopathological features.
Variable No. %
Age, years  
  40-49 2 6.66
  50-59 7 23.33
  60-69 10 33.33
  70-79 9 30
  >80 2 6.66
  Mean 65.66 
  Median 65.5 
  Maximum  80 
  Minimum  48 
TNM pT  
  3a 2 6.6
  3b 3 10
  2b 2 6.7
  2c 23 76.7
TNM pN  
  0 27 90
  1 3 10
TNM pM  
  x 27 90
  0 2 6.66
  1 1 3.33
Gleason score  
  7 19 63.3
  <7 8 26.7
  >7 3 10
PSA, ng/ml  
  >10 21 70
  4-10 9 30
  <10 0 0
TNM, Tumor-Node-Metastasis; pT, local extension of primary 
tumor; pN, regional lymph node; pM, distant metastasis status; PSA, 
prostate‑specific antigen.
Table II. Primers for 13 selective microRNAs (forward)a and 
genes (forward and reverse).
MicroRNA/gene Sequence
1301-3p 5'-TTGCAGCTGCCTGGGAGTGAC
 TTC-3'
193b-3p 5'-AACTGGCCCTCAAAGTCCCGCT-3'
206  5'-TGGAATGTAAGGAAGTGTGTGG-3'
1266-5p 5'-CCTCAGGGCTGTAGAACAGG
 GCT-3'
133b  5'-TTTGGTCCCCTTCAACCAGCTA-3'
653-5p 5'-GTGTTGAAACAATCTCTACTG-3'
143-3p 5'-TGAGATGAAGCACTGTAGCTC-3'
219a-5p 5'-TGATTGTCCAAACGCAATTCT-3'
185-5p 5'-TGGAGAGAAAGGCAGTTCC
 TGA-3'
126-3p 5'-TCGTACCGTGAGTAATAATGCG-3'
126-5p 5'-CATTATTACTTTTGGTACGCG-3'
30c-2-3p 5'-CTGGGAGAAGGCTGTTTACTCT-3'
BCL2 forward  5'-GGATCCAGGATAACGGAGGC-3'
BCL2 reverse 5'-GGCAGGCATGTTGACTTCAC-3'
BCL2L1 forward 5'-CCTTGGATCCAGGAGAACGGC-3'
BCL2L1 reverse 5'-GGGAGGGTAGAGTGGATGGTC-3'
GAPDH forward 5'-AACGGGAAGCTTGTCATCAATGG
 AAA-3'
GAPDH reverse 5'-GCATCAGCAGAGGGGGCAGAG-3'
aThe reverse primer sequence was not provided by the manufacturer. 
BCL2, B cell lymphoma 2; BCL2L1, BCL2-like 1.
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RT‑qPCR
microRNAs. RT-qPCR for the analysis of selected microRNAs 
was performed in a Rotor-Gene 6000 (Corbett Life Science; 
Qiagen GmbH, Hilden, Germany) with 7 µl qPCR Master 
mix 2x, 1 µl universal reverse-primer sequence (as mentioned 
earlier), in addition to a specific forward primer (Table II). The 
SNORD47 (U47) and U6 microRNAs were used as reference 
genes. The thermocycling conditions were as follows: 95˚C 
for 15 min, 40 cycles of 94˚C for 15 sec, 55˚C for 30 sec and 
70˚C for 30 sec. The quantitative cycle (CQ) was defined as a 
fractional cycle at which the fluorescence of the sample passes 
through the defined threshold. Analysis of the RT‑qPCR data 
was performed using the 2‑∆∆Cq method, which is defined as 
follows:
Δ Cq (sample)=Cq (target microRNA sample)-Cq 
(reference microRNA sample)
Δ Cq (control)=Cq (target microRNA control)-Cq 
(reference microRNA control)
ΔΔ Cq=Δ Cq (sample)-Δ Cq (control)
Normalized target gene expression level=2-ΔΔCq
mRNAs. First strand cDNAs were subjected to RT-qPCR 
using SYBR® Premix Ex Taq™ (Tli RNase H Plus; Takara 
Biotechnology Co., Ltd., Dalian, China). Reactions (20 ml) 
were used containing forward and reverse primers for the 
BCL2, BCL2-XL target genes and the GAPDH gene as the 
normalizer (Table II). The thermocycling conditions were 
as follows: 1 cycle at 95˚C for 30 sec; 40 cycles at 95˚C 
for 5 sec and 60˚C for 20 sec. Analysis of the RT‑qPCR 
results was performed as described earlier. All primers 
were synthesized by TAG Copenhagen A/S (Copenhagen, 
Denmark).
Statistical analysis. The relative expressions of 12 miRNAs in 
PCa and BPH tissue samples were compared using a Student's 
t-test with Welche's correction. Data are presented as the 
mean ± standard deviation. P<0.05 was considered to indicate 
a statistically significant difference. GraphPad Prism 5 soft-
ware (GraphPad Software, Inc., La Jolla, CA, USA) was used 
for calculations and drawing graphs.
Results
miRNA selection. The results obtained from the four 
aforementioned databases are presented in Table III. A total 
of 12 miRNAs were selected based on the highest scores. 
Furthermore, previously validated miRNAs that were 
differentially downregulated in cancer cells were considered.
Table III. Selection of microRNAs using 4 algorithmsa.
Name Gene miRanda miRDB miRWalk Target scan Individual score Overall score
miR-30C-2-3P BCL2 1 0 1 1 3 6
 BCL2L1 1 0 1 1 3 
miR-126-3P BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
miR-126-5P BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
miR-185-5P BCL2 1 0 1 1 3 5
 BCL2L1 1 0 0 1 2 
miR-219a-5P BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
miR-1301-3P BCL2 1 1 0 1 3 4
 BCL2L1 1 0 0 0 1 
miR-193b-3P BCL2 0 0 0 0 0 3
 BCL2L1 1 0 1 1 3 
miR-653b-5P BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
miR-143-3P BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
miR-133b BCL2 0 0 0 0 0 3
 BCL2L1 1 0 1 1 3 
miR-1266-5p BCL2 1 0 1 1 3 6
 BCL2L1 1 0 1 1 3 
miR-206 BCL2 1 0 1 1 3 3
 BCL2L1 0 0 0 0 0 
a1, microRNA targets specified gene; 0, microRNA does not target specified gene. miR, microRNA; BCL2, B cell lymphoma 2; 
BCL2L1, BCL2-like 1.
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Expression analysis in clinical samples. Initially, to evaluate 
RT‑qPCR proliferation efficiency, which was measured as the 
ability to double the quantity of the target molecules with each 
cycle, of selected miRNAs, 4 serial dilutions of a pooled cDNA 
sample were tested with each set of primers (data not shown).
The expression of candidate miRNAs in PCa cancer and 
BPH tissues was evaluated by RT-qPCR and the results were 
normalized to U6 and U47 miRNA expression and mentioned 
earlier. Among the 12 miRNAs that were evaluated for 
expression in clinical samples, miR-1266-5p, miR-185-5p and 
miR-30c-2-3p were downregulated in PCa samples compared 
with BPH samples (Fig. 1).
Furthermore, expression analysis of the BCL2 and BCL2L1 
genes revealed that the two genes were upregulated in PCa 
samples compared with expression in BPH samples (Fig. 2).
Expression analysis in PC3 and DU145 cell lines compared with 
HUVECs. The expression of miR-185-5p and miR-30c-2-3p 
was downregulated in DU145 and PC3 cells compared with 
expression in HUVECs when U6 or U47 housekeeping genes 
were used as the normalizers. With respect to PC3 cells, 
miR‑1266‑5p expression was also significantly downregulated 
when U47 was employed as the normalizer (Fig. 3).
Expression of the BCL2 gene was upregulated in the DU145 
cells compared with expression in the HUVECs; however, 
expression of this gene in the PC3 cells was not significantly 
altered. On the other hand, expression of the BCL2L1 gene was 
increased in the DU145 and PC3 cells compared with expres-
sion in the HUVECs (Fig. 4).
In conclusion, the expression of 3 miRNAs (miR-1266-5p, 
miR-185-5p and miR-30c-2-3p) was downregulated in clinical 
PCa tissue samples and PCa cell lines.
Discussion
The principal aim of cancer treatment is the complete removal 
of cancer cells without causing changes to the rest of the body. 
Over the last few decades, microRNAs have demonstrated 
potential in cancer treatment. These molecules are able to 
regulate the expression of proteins involved in different impor-
tant cellular pathways, including the cell cycle and apoptosis. 
Downregulation of certain miRNAs has been observed in 
numerous types of cancer (23,24), and molecular therapy 
studies have revealed the usefulness of miRNA overexpression 
in cancer treatment in vitro and in vivo (25).
The present study aimed to determine whether the 
downregulation of miRNAs targeting two anti-apoptotic genes 
(BCL2 and BCL2L1) may be associated with the molecular 
pathogenesis of PCa. In order to examine this, a few miRNA 
candidates were selected using bioinformatics tools, and their 
expression was analyzed in clinical tissue samples obtained 
from patients with PCa and compared with their expression 
in BPH tissue samples. Among 12 miRNA candidates, 
3 exhibited downregulation that was counter-regulated with 
the expression of two target genes.
The results of the present study are supported by those of 
previous studies, which evaluated the expression of selected 
miRNAs in various cancer tissues. In 2014, Chen et al (23) 
demonstrated that miR-1266 was downregulated in 58 patients 
with gastric cancer; however, it was indicated that miR-1266 
binds to the 3'-UTR of the human telomerase reverse tran-
scriptase gene and that its expression in gastric cancer tissues 
was reduced in comparison with the normal group (23).
Figure 1. The expression of candidate microRNAs in prostate cancer tissues compared with benign prostatic hyperplasia tissues (normalized to U6 and U47). 
*P<0.05 and **P<0.01, compared with benign prostatic hyperplasia tissue. miR, microRNA.
Figure 2. Relative expression of BCL‑2 and BCL2L1 genes in prostate cancer 
tissues compared with benign prostatic hyperplasia tissues (normalized to 
GAPDH). **P<0.01. BCL-2, B-cell lymphoma 2; BCL2L1, BCL-2-Like 1.
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In another study, the expression of miR-185 in breast 
cancer tissues was reduced in comparison to the control group. 
The authors demonstrated that overexpression of miR-185 may 
inhibit the proliferation of breast cancer cells (26). The study 
demonstrated that miR-185 binds to the 3'-UTR region of the 
vascular endothelial growth factor A (VEGF-A) gene and 
there was also a significant inverse association between the 
expression of miR-185 and that of VEGF-A (26). Of note, the 
alignment of miR-185 with the 3'-UTR sequences of VEGF-A 
and BCL2 mRNAs exhibited similarity in the seed region 
sequence (www.microrna.org; Fig. 5). It is likely that miR-185 
is also able to target the BCL2 gene. In this case, overexpres-
sion of miR-185 in cancer cells may inhibit angiogenesis while 
simultaneously promoting apoptosis.
Furthermore, the reduced miR-185 expression has been 
observed in another study performed in 2010 (27). The 
investigators observed downregulation of miR-185 in ovarian 
cancer, pediatric renal tumors and multiple breast cancer cell 
lines. Additionally, it was demonstrated that overexpression of 
miR-185 was able to reduce the expression of the SIX1 onco-
gene, which induces apoptosis in apoptosis-resistant cancer 
cells (27). Furthermore, has-miR-185 exhibits an identical 
binding sequence to the seed region sequences of SIX1 and 
BCL2 mRNAs (www.microrna.org; Fig. 5).
In another study, Zhang et al (28) revealed a significant 
downregulation of miR-30c in colon cancer tissue samples 
and in the colon cancer HCT-116 cell line (28). Additionally, 
overexpression of miR-30c resulted in the inhibition of cancer 
cell proliferation, migration and invasion (28). Although they 
validated targeting of the ADAM19 gene by miR-30c and 
proposed that ʻmiR‑30c inhibited cancer cells via targeting 
ADAM19 ,ʼ this observation may be, at least in part, due to 
simultaneous targeting of the BCL2L1 gene by miR-30c, as 
the seed sequence binding sites of these genes are similar 
(Fig. 5). The results of the present study demonstrated that 
downregulation of miR-30c was paralleled with overexpres-
sion of the BCL2L1 gene. However, this assumption requires 
further confirmation in future studies.
In 2012, researchers revealed that miR-491 overexpression 
may induce apoptosis in pancreatic cancer SW1990 cells by 
targeting the 3'-UTR of the BCL2L1 gene. The seed match 
sequence region of the BCL2L1 gene was confirmed by muta-
genesis tests (29). Targeting of the BCL2L1 anti-apoptotic 
gene by miR-491 and the subsequent reduction of cancer 
cell phenotype (i.e., apoptosis), supports the hypothesis of 
the present study, that downregulation of miR-30c may cause 
overexpression of its target, the BCL2L1 gene, eventually 
halting cell apoptosis.
In 2012, Zhao et al (30) confirmed by luciferase reporter 
assay that miR-125b was able to bind to the 3'-UTR of 
the BCL2 gene, which had previously been predicted in 
bioinformatics analysis. The same study also demonstrated 
that miR-125b suppressed hepatocellular carcinoma cell 
Figure 3. Relative expression of miR-1266, miR-185 and miR30C (normalized to U6 and U47) in PC3 and DU145 cells lines, compared with human umbilical 
vein endothelial cells. *P<0.05, **P<0.01 and ***P<0.001, compared with human umbilical vein endothelial cells. miR, microRNA.
Figure 4. Relative expression of BCL2 and BCL2L1 genes (normalized to 
GAPDH) in PC3 and DU145 cell lines, compared with human umbilical 
vein endothelial cells. BCL-2, B-cell lymphoma 2; BCL2L1, BCL-2-Like 1. 
**P<0.01, compared with human umbilical vein endothelial cells.
Figure 5. Prediction of miR-185 seed sequence complementary to 3'-untrans-
lated region targets of (A) BCL2 mRNA (NM_000633), (B) VEGFA mRNA 
(NM_003376) and (C) SIX1 mRNA (NM_005982). miR, microRNA; 
VEGFA, vascular endothelial growth factor A.
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proliferation and promoted apoptosis by inhibiting the 
gene expression of BCL2 (30). Another study, which was 
performed in 2014, revealed that miR-16 was downregulated 
in human brain glioma tissues and that overexpression of 
miR-16 suppressed the expression of BCL2 and promoted 
cell apoptosis (31). Additionally, overexpression of miR-16 
in a human glioma nude mouse model confirmed tumor 
growth suppression (31). A 2011 study on the human 
non-small cell lung cancer (NSCLC) A549 cell line indi-
cated that miR-7 expression in the NSCLC cell line was 
reduced, while overexpression of miR-7 resulted in the 
suppression of A549 cell proliferation, as well as the induc-
tion of apoptosis (32). Furthermore, in the same study, 
miR-7 binding to the 3'-UTR of the BCL2 gene was been 
confirmed by bioinformatics prediction and luciferase 
reporter assay (32).
In general, downregulation of miR-1266, miR-185 and 
miR-30c has been previously reported in several different 
types of cancer cells. However, interventional studies have 
demonstrated that overexpression of various miRs targeting 
the BCL2 and BCL2L1 genes may improve cell apoptosis. 
Furthermore, the results of the present study demonstrated 
concordance between bioinformatics prediction and/or litera-
ture review with expression analysis of miR-1266, miR-185 
and miR30c, as well as the BCL2 and BCL2L1 genes, in PCa 
tissues and PCa cell lines. It is likely that overexpression of 
these 3 microRNAs may suppress the proliferation of tumor 
cells via upregulation of the apoptosis pathway. Notably, 
further investigations are necessary in order to confirm 
whether or not selected microRNAs are bound to the 3'-UTR 
of the BCL2 and BCL2‑XL genes and reduce their expres-
sion in PCa cell lines; and whether or not overexpression of 
microRNAs reduces the expression of target genes, and if the 
latter is co-incident with changes in cancerous phenotypes, 
including cell apoptosis promotion, cell proliferation reduction 
or cell cycle attenuation.
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